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Letters
AntimicrobiAl resistAnce in 
CampylobaCter isolAtes from sporAdic 
cAses of Acute humAn gAstroenteritis in 
northern irelAnd
Editor, 
Thermophilic campylobacters, particularly Campylobacter 
jejuni, continue to remain the most common cause of acute 
bacterial enteritis in Northern Ireland. Most recent confirmed 
data for 2006 recorded 937 laboratory reports for Northern 
Ireland (http://www.cdscni.org.uk/surveillance/Gastro/
Campylobacter_sp.htm), approximating to 53.8 cases per 
100,000 individuals, compared to an attack rate of 86.7 and 
42.8 cases per 100,000 individuals for England & Wales 
and the Republic of Ireland, respectively.  However, in a 
previous epidemiological study1, it was estimated that the 
true prevalence of this infection was approximately 10.3-fold 
higher, due to patient under-reporting.
In relation to antibiotic resistance of local campylobacters, 
we have continued to map resistance trends2,3 during the 
perod 2004-2007 (n=1102) (Table I). The worrying finding 
of this study has been the marked increase in resistance to 
ciprofloxacin, rising to 31.7% in 2007, which is the highest 
level of resistance of these organisms to this agent that has ever 
been reported in Northern Ireland. Susceptibility data relating 
to ciprofloxacin resistance in local human clinical isolates 
were first reported in 1996 (9%) and this resistance rate has 
since risen steadily.  Presently, the reason(s) for this increase 
in resistance is unclear. The most likely explanation for this is 
the ingestion of campylobacters which are more resistant to 
this agent, rather than the acquisition of resistance de novo in 
the human gastrointestinal tract, epecially as these organisms 
do not form part of the ecological microflora of the human 
gut. This therefore encourages examination of reservoirs 
and sources where such resistant organisms may enter the 
food chain. One possibility may be consumption of imported 
poultry meat from origins outside the EU, where veterinary 
controls of the use antibiotics in animal husbandry may not be 
stringent, thus leading to the development of fluoroquinolone 
resistant isolates in chickens prior to slaughter. A previous 
report in 20034 described the importation to Northern 
Ireland of 500 tonnes of chicken meat per week, which had a 
resistance to ciprofloxacin of 14% of isolates tested.  Similar 
studies from Belgium5 and Spain have suggested ciprofloxacin 
resistance in poultry to be 42% and 99%, respectively.
Another explanation for this rise in ciprofloxacin resistance 
in local human infections may be the acquisition  of more 
resistant strains outside of Northern Ireland, particularly 
relating to travel abroad. The arrival of several budget and low 
cost airlines to Northern Ireland has lead to a marked increase 
in Northern Ireland residents travelling to countries which 
have a higher endemic rate of fluoroquinolone-resistance in 
campylobacters originating from animals, as well as humans. 
In 2007, airport passenger traffic to EU destinations increased 
by 21% at Belfast International Airport, resulting in 1,490, 
775 passenger journeys (http://www.caa.co.uk/docs/80/
airport_data/2007Annual/Table_10_1_EU_and_Other_
Intl_Pax_Traffic_2007.pdf). Urgent attention now needs to 
be directed at this resistance issue in order to ascertain the 
origins of this marked rise in ciprofloxacin-reisitance in local 
campylobacters.
In conclusion, primary care practitioners, specialists in 
infectious diseases, microbiologists and epidemiologists 
need to be aware of the local increase in antibiotic resistance 
of thermophilic campylobacters to ciprofloxacin (31.2%) 
and the relative susceptibility of local wildtype isolates to 
erythromycin (1.2%).
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Table I:
Percentage of wildtype Campylobacter isolates resistant to 
three antibiotic agents over the period 2004-2007.
Year
Antibiotic 2004
(n=237)
2005
(n=297)
2006
(n=309)
2007
(n=259)
Ciprofloxacin 20.3% 18.9% 23.6% 31.7%
Erythromycin 2.5% 3.4% 1.9% 1.2%
Tetracycline 20.2% 19.5% 19.7% 22.8%
